Clade 2.3.4.4 H5 chimeric cold-adapted attenuated influenza vaccines induced cross-reactive protection in mice and ferrets

J Virol. 2023 Nov 30;97(11):e0110123. doi: 10.1128/jvi.01101-23. Epub 2023 Nov 2.

Abstract

Clade 2.3.4.4 H5Nx avian influenza viruses (AIVs) have circulated globally and caused substantial economic loss. Increasing numbers of humans have been infected with Clade 2.3.4.4 H5N6 AIVs in recent years. Only a few human influenza vaccines have been licensed to date. However, the licensed live attenuated influenza virus vaccine exhibited the potential of being recombinant with the wild-type influenza A virus (IAV). Therefore, we developed a chimeric cold-adapted attenuated influenza vaccine based on the Clade 2.3.4.4 H5 AIVs. These H5 vaccines demonstrate the advantage of being non-recombinant with circulated IAVs in the future influenza vaccine study. The findings of our current study reveal that these H5 vaccines can induce cross-reactive protective efficacy in mice and ferrets. Our H5 vaccines may provide a novel option for developing human-infected Clade 2.3.4.4 H5 AIV vaccines.

Keywords: H5Nx influenza viruses; cold-adapted attenuated influenza vaccine; ferrets; immunity; mice.

MeSH terms

  • Animals
  • Antibodies, Viral
  • Cross Protection*
  • Ferrets
  • Influenza A virus*
  • Influenza Vaccines* / genetics
  • Influenza in Birds
  • Mice
  • Orthomyxoviridae Infections* / prevention & control
  • Vaccines, Attenuated

Substances

  • Antibodies, Viral
  • Influenza Vaccines
  • Vaccines, Attenuated